Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 2, 2007, Pages 231-235

  Llamas Esperón, Guillermo A ^a   Sandoval Navarrete, Santiago ^a  

^a Hospital Cardiológica Aguascalientes Aguascalientes   (Mexico)

Author keywords

Cardiomyopathy; Gelatin sponge; Myocardial ablation; Myocardial infarction

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATINE KINASE; GELATIN SPONGE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY; ARTERY OCCLUSION; ARTICLE; ARTIFICIAL EMBOLISM; BIODEGRADABLE IMPLANT; CASE REPORT; CLINICAL FEATURE; DYSPNEA; FOLLOW UP; HEART INFARCTION; HEART SEPTUM ARTERY; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; SYMPTOM; SYNCOPE; THORAX PAIN; THROMBOSIS;

BALLOON DILATATION; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY ANGIOGRAPHY; GELATIN SPONGE, ABSORBABLE; HUMANS; MALE; MIDDLE AGED;

EID: 33846799229     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20935     Document Type: Article

References (23)

1. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-670.
2. Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-258.
3. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: Clinical analysis of 126 patients with emphasis on natural history. Circulation 1968;37:759-788.
4. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995;92:1680-1692.
5. Marian AJ, Mares A Jr, Kelly DP, et al. Sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 1995;16:368-376.
6. Seggewiss H. Medical therapy versus interventional therapy in hypertrophic obstructive cardiomyopathy. Curr Control Trials Cardiovasc Med 2000;1:115-119.
7. Fananapazir L, Epstein ND, Curiel RV, Panza JA, tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-2742.
8. Bircks W, Schulte HD. Surgical treatment of hypertrophic obstructive cardiomyopathy with special reference to complications and atypical hypertrophic obstructive cardiomyopathy. Eur Heart J 1983;4(Suppl F):187-190.
9. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
10. Nasser ML, Sherif FN, Kay D, Donna K, William HS. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000;36:852-855.
11. Shamin W, Yousufuddin M, Wang D, et al. Nonsurgical reduction of the intraventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002;347:1326-1333.
12. Nagueh SF, Ommen SR, Lakkis NM, et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. J Am Coll Cardiol 2001;38:1701-1706.
13. Abbas AE, Brewington SD, Dixon SR, Grines CL, O'Neill WW. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. J Interv Cardiol 2005;18:155-162.
14. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38:1994-2000.
15. Honda T, Sakamoto T, Miyamoto S, Sugiyama S, Yoshimura M, Ogawa H. Successful coronary stenting of the left anterior descending artery at the branching site of the targeted septal perforator immediately after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Intern Med 2005;44:722-726.
16. Gaspar J, Martinez-Ríos MA, Vonderwalde C, Rosas M, et al. Pericardium-covered stent for septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv 1999;47:73-79.
17. Iacob M, Pinte F, Tintoin I, et al. Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004;61:350-354.
18. Lafont A, Durand E, Brasselet C, et al. Percutaneous transluminal septal coil embolisation as an alternative to alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 2005;91:92.
19. Gilbert BW, Pollick C, Adelman AG, Wigle ED. Hypertrophic cardiomyopathy: Subclassification by M-mode echocardiography. Am J Cardiol 1980;45:861-872.
20. Alain T, Drooz MD, Curtis A, Lewis MD, Timothy E, Allen MD, et al. Quality improvement guidelines for percutaneous transcatheter embolization. J Vasc Interv Radiol 2003;14:S237-S242.
21. Bradham WS Jr, Gunasinghe BS, Holder JR, et al. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2002;40:2165-2173.
22. Agarwall SC, Purcell IF, Furniss SS. Apical myocardial injury caused by collateralisation of a septal artery during ethanol septal ablation. Heart 2005;91:e2.
23. Seggewiss H, Rigopoulos A, Faber L, Ziemssen P. Percutaneous septal in hypertrophic obstructive cardiomyopathy - indication, technique, and results. EuroPCR 2003;14:283-293.